Loading...
Modalis Therapeutics Corporation
4883.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥91.00
¥0.00(0.00%)
Modalis Therapeutics Corporation (4883.T) Financial Performance & Income Statement Overview
Review Modalis Therapeutics Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
43.57%
↑ 43.57%
Net Income Growth
44.90%
↑ 44.90%
Operating Cash Flow Growth
36.48%
↑ 36.48%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-57.68%
↓ 57.68%
ROIC
-44.40%
↓ 44.40%
Modalis Therapeutics Corporation (4883.T) Income Statement & Financial Overview
Review Modalis Therapeutics Corporation's (4883.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $1.02B | $165.64M | $293.91M | $422.60M |
| SG&A Expenses | $65.23M | $57.80M | $54.95M | $67.48M |
| Operating Expenses | $275.25M | $223.44M | $348.87M | $490.09M |
| Total Costs & Expenses | $275.25M | $223.44M | $348.87M | $490.09M |
| Interest Income | $0.00 | $0.00 | $1000.00 | $7000.00 |
| Interest Expense | $0.00 | $0.00 | $1.02M | $1.03M |
| Depreciation & Amortization | $183000.00 | $183000.00 | $183.00 | $33.67M |
| EBITDA | -$1.09B | -$223.26M | -$321.68M | -$456.60M |
| EBITDA Ratio | ||||
| Operating Income | -$275.25M | -$223.44M | -$348.87M | -$490.09M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $17.63M | -$55.53M | $26.16M | $32.45M |
| Income Before Tax | -$257.62M | -$278.97M | -$322.71M | -$457.63M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $44000.00 | $315000.00 | $303000.00 | $303000.00 |
| Net Income | -$257.66M | -$279.29M | -$323.01M | -$457.94M |
| Net Income Ratio | ||||
| EPS | -$3.81 | -$6.09 | -$8.41 | -$13.57 |
| Diluted EPS | -$3.81 | -$6.09 | -$8.41 | -$13.57 |
| Weighted Avg Shares Outstanding | $67.61M | $45.84M | $38.40M | $33.74M |
| Weighted Avg Shares Outstanding (Diluted) | $67.61M | $45.84M | $38.40M | $33.74M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan